Mostrar el registro sencillo del ítem

dc.contributor.authorCastilla Catalán, Jesús
dc.contributor.authorNavascués, Ana
dc.contributor.authorCasado, Itziar
dc.contributor.authorPérez-García, Alejandra
dc.contributor.authorAguinaga, Aitziber
dc.contributor.authorEzpeleta, Guillermo
dc.contributor.authorPozo Sanchez, Francisco 
dc.contributor.authorEzpeleta, Carmen
dc.contributor.authorMartínez-Baz, Iván
dc.date.accessioned2020-01-30T09:32:54Z
dc.date.available2020-01-30T09:32:54Z
dc.date.issued2018
dc.identifier.citationEuro Surveill. 2018 Feb;23(7).es_ES
dc.identifier.issn1560-7917es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8993
dc.description.abstractThe 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.es_ES
dc.description.sponsorshipThis study was supported by the Horizon 2020 program of the European Commission (agreement 634446); by the I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) Network funded by the European Centre for Disease Prevention and Control; and by the Carlos III Institute of Health with the European Regional Development Fund (CM15/00119, INT16/00122).es_ES
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCase-control studyes_ES
dc.subjectInfluenzaes_ES
dc.subjectInfluenza vaccinees_ES
dc.subjectInfluenza-like illnesses_ES
dc.subjectRepeated vaccinationes_ES
dc.subjectVaccine effectivenesses_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshCase-Control Studies es_ES
dc.subject.meshChild es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtype es_ES
dc.subject.meshInfluenza B virus es_ES
dc.subject.meshInfluenza Vaccines es_ES
dc.subject.meshInfluenza, Humanes_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshSpain es_ES
dc.subject.meshVaccination es_ES
dc.subject.meshYoung Adult es_ES
dc.subject.meshSeasons es_ES
dc.subject.meshSentinel Surveillance es_ES
dc.titleInterim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29471624es_ES
dc.format.volume23es_ES
dc.format.number7es_ES
dc.identifier.doi10.2807/1560-7917.ES.2018.23.7.18-00057es_ES
dc.contributor.funderUnión Europea 
dc.contributor.funderEuropean Centre for Disease Prevention and Control 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1560-7917es_ES
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2018.23.7.18-00057es_ES
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDHorizon 2020 program of the European Commission (agreement 634446)es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CM15/00119es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/INT16/00122es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional